Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 186Diabetes Treatment and ManagementBariatric Surgery and OutcomesDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index; 46 of the 60 sources its claims cite were checked for support.

5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study

Open access

Abstract

Background In DiRECT, a randomised controlled effectiveness trial, weight management intervention after 2 years resulted in mean weight loss of 7·6 kg, with 36% of participants in remission of type 2 diabetes. Of 36 in the intervention group who maintained over 10 kg weight loss at 2 years, 29 (81%) were in remission. Continued low-intensity dietary support was then offered up to 5 years from baseline to intervention participants, aiming to maintain weight loss and gain clinical benefits. This extension study was designed to provide observed outcomes at 5 years. Methods The DiRECT trial took place in primary care practices in the UK. Participants were individuals aged 20–65 years who had less than 6 years' duration of type 2 diabetes, a BMI greater than 27 kg/m 2 , and were not on insulin. The intervention consisted of withdrawal of antidiabetic and antihypertensive drugs, total diet replacement (825–853 kcal per day formula diet for 12–20 weeks), stepped food reintroduction (2–8 weeks), and then structured support for weight-loss maintenance. After sharing the 2-year results with all participants, UK National Health Service data were collected annually until year 5 from remaining intervention participants who received low-intensity dietary support, intervention withdrawals, and the original randomly allocated groups. The primary outcome was remission of type 2 diabetes; having established in the DiRECT trial that sustained weight loss was the dominant driver of remission, this was assumed for the Extension study. The trial is registered with the ISRCTN registry, number 03267836. Findings Between July 25, 2014, and Aug 5, 2016, 149 participants were randomly assigned to the intervention group and 149 were assigned to the control group in the original DiRECT study. After 2 years, all intervention participants still in the trial (101 [68%] of 149) were approached to receive low-intensity support for a further 3 years. 95 (94%) of 101 were able to continue and consented and were allocated to the DiRECT extension group. 54 participants were allocated to the non-extension group, where intervention was withdrawn. At 5 years, DiRECT extension participants (n=85) lost an average of 6·1 kg, with 11 (13%) of 85 in remission. Compared with the non-extension group, DiRECT extension participants had more visits with HbA 1c <48 mmol/mol (<6·5%; 36% vs 17%, p=0·0004), without glucose-lowering medication (62% vs 30%, p<0·0001), and in remission (34% vs 12%, p<0·0001). Original control participants (n=149) had mean weight loss 4·6 kg (n=82), and 5 (5%) of 93 were in remission. Compared with control participants, original intervention participants had more visits with weight more than 5% below baseline (61% vs 29%, p<0·0001), HbA 1c below 48 mmol/mol (29% vs 15%, p=0·0002), without antidiabetic medication (51% vs 16%, p<0·0001), and in remission (27% vs 4%, p<0·0001). Of those in remission at year 2, 26% remained in remission at 5 years. Serious adverse events in the original intervention group (4·8 events per 100 patient-years) were under half those in the control group (10·2 per 100 patient-years, p=0·0080). Interpretation The extended DiRECT intervention was associated with greater aggregated and absolute weight loss, and suggested improved health status over 5 years. Funding Diabetes UK.

Overview

CoChat Summary

TL;DR

In the 5-year extension of DiRECT, continued low-intensity dietary support after 2 years was associated with maintained weight loss and better aggregated glycaemic outcomes than no extension, but remission rates fell substantially by year 5. The authors report observational differences beyond the original randomised period, with weight regain and loss of remission common.

Key findings

  • At 5 years, DiRECT extension participants (n=85) had lost a mean of 6·1 kg, and 11 (13%) of 85 were in remission; among those in remission at year 2, 26% remained in remission at 5 years.
  • Compared with the non-extension group, extension participants had more follow-up visits with HbA1c <48 mmol/mol (36% vs 17%, p=0·0004), without glucose-lowering medication (62% vs 30%, p<0·0001), and in remission (34% vs 12%, p<0·0001).
  • Compared with original control participants, original intervention participants had more visits with weight >5% below baseline (61% vs 29%, p<0·0001), HbA1c <48 mmol/mol (29% vs 15%, p=0·0002), without antidiabetic medication (51% vs 16%, p<0·0001), and in remission (27% vs 4%, p<0·0001).
  • Serious adverse events in the original intervention group were 4·8 per 100 patient-years versus 10·2 per 100 patient-years in the control group (p=0·0080).

Methods

  • Extension of the UK primary care DiRECT trial: 298 adults aged 20–65 years with type 2 diabetes duration <6 years, BMI >27 kg/m², and not on insulin were originally randomised to intervention or control. After 2 years, 101 remaining intervention participants were offered low-intensity support for 3 further years; 95 consented and formed the DiRECT extension group, while 54 withdrew and formed the non-extension group.
  • Routinely collected NHS data were gathered annually to 5 years for original intervention and control participants; outcomes included bodyweight, HbA1c, other biochemistry, medication use, remission (HbA1c <48 mmol/mol without glucose-lowering medication), quality of life, and clinical events.
  • Analyses used t-tests, Fisher’s exact tests, bootstrapping with 10,000 replicated datasets, and negative binomial or Poisson regression for event rates; data were reported descriptively without imputation or adjustment for multiple comparisons.

Limitations

  • The paper states that the extension group was self-selected by remaining engaged at 2 years; control participants were strongly encouraged to control weight after the randomised trial, so their outcomes do not reflect usual care, and differences beyond 2 years might not reflect intervention.
  • The paper states that the original trial was powered to detect 1-year remission differences, not longer-term or other outcomes; years 3–5 were observational, analyses were unadjusted and without imputation, and sparse data bias may affect event estimates.
  • The paper notes that many outcomes could not be measured in routine primary care, extension participants were older and probably more health-aware than non-extension participants, and COVID-19 restrictions curtailed planned review appointments and relapse management.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(23)00385-6

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

23 Valid · 10 Not valid · 10 Not checked · 167 Own results and interpretations

96 more claims · 7 with their cited sources checked

Create a free account to see all 210 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 56
  • It may state two separate claims as one. 74
  • Borderline: one of the tests for a substantial claim is unclear. 1
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 53 references

Research works printed but not linked: 2

  1. Gregg, 2024, Impact of remission from type 2 diabetes on long-term health outcomes: findings from the Look AHEAD study, Diabetologia, 67, 459, 10.1007/s00125-023-06048-6 · DOI · Paper page
  2. Brosnahan, 2021, Brief formula low-energy-diet for relapse management during weight loss maintenance in the Diabetes Remission Clinical Trial (DiRECT), J Hum Nutr Diet, 34, 472, 10.1111/jhn.12839 · DOI · Paper page

Cited by

See all 186

Metadata

Authors
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Kelly, T., Irvine, K., Peters, C., Zhyzhneuskaya, S., Hollingsworth, K. G., Adamson, A. J., Sniehotta, F. F., Mathers, J. C., McIlvenna, Y., Welsh, P., McConnachie, A., McIntosh, A., Sattar, N., & Taylor, R.
Affiliations
  • University of Glasgow (GB)
  • Newcastle University (GB)
  • Heidelberg University (DE)
Corresponding author
Lean, Michael EJ
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2024-04
Volume
12
Issue
4
Pages
233-246
ISSN
2213-8587 (ISSN-L)
OpenAlex
W4392163265
Cited by
186
References
53
Citations by year
2026: 73 · 2025: 87 · 2024: 26
FWCI
60.84
Type
journal article
Language
en
Update notices
erratum (2024-06-01)
Open access
Licence
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Funders
Diabetes UK (19/0005976, 13/0004691)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes remission, weight loss maintenance, total diet replacement, long-term follow-up, primary care, antihypertensive drug withdrawal, sustained weight loss, extension study, National Health Service
MeSH terms
Diabetes Mellitus, Type 2, Follow-Up Studies, United Kingdom, Humans, Hypoglycemic Agents, State Medicine, Weight Loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. https://app.cochat.ai/papers/10.1016/s2213-8587(23)00385-6
The paper
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Kelly, T., Irvine, K., Peters, C., Zhyzhneuskaya, S., Hollingsworth, K. G., Adamson, A. J., Sniehotta, F. F., Mathers, J. C., McIlvenna, Y., Welsh, P., McConnachie, A., McIntosh, A., Sattar, N., & Taylor, R. (2024). 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(23)00385-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.